Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. πŸ… He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. πŸŽ“ His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. πŸŽ“ Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. πŸ’Š He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. πŸ† This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. πŸ’‘ Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Edwin Posadas | Precision Medicine | Best Researcher Award

Edwin Posadas | Precision Medicine | Best Researcher Award

Dr. Edwin Posadas, Cedars-Sinai Cancer, United States

Dr. Edwin M. Posadas is a distinguished oncologist and urologist specializing in prostate cancer research and treatment. He is a Professor at Cedars-Sinai Medical Center and UCLA, co-Director of the Cancer Therapeutics Program, and Medical Director of the Urologic Oncology Program. A Johns Hopkins graduate, he trained at the NIH and University of Michigan. Dr. Posadas has earned numerous accolades, including Castle Connolly Top Doctor and Sigma Xi Honors. An active researcher, mentor, and leader in oncology, he contributes to multiple scientific committees and journals, shaping the future of cancer care. πŸ“šπŸ”¬βœ¨

Publication Profile

orcid

Education

Dr. Edwin Posadas πŸŽ“ began his academic journey at Johns Hopkins University, earning dual B.E.S. degrees in Biomedical and Chemical Engineering (1993) with summa cum laude honors. His studies focused on biological transport systems and physiological fluid mechanics. He then pursued his M.D. at Johns Hopkins School of Medicine (1998) 🩺, followed by an internship and residency at the University of Michigan Medical Center (2001) πŸ₯. Further specializing, he completed a fellowship in Medical Oncology and Hematology (2005) 🧬 at the National Cancer Institute & National Heart, Lung, and Blood Institute, solidifying his expertise in cancer research and treatment. πŸ”¬πŸ’™

Professional Associations

Dr. Edwin Posadas 🩺 is an esteemed member of numerous professional associations and scholarly societies, reflecting his dedication to oncology, urology, and medical ethics. He joined the American Medical Association (1993) πŸ₯, Association of Philippine Physicians of America (1998) πŸ‡΅πŸ‡­, and American College of Physicians (1998) 🩻, later becoming a Fellow (2010) πŸŽ–οΈ. His contributions extend to the American Society of Clinical Oncology (2001) 🧬, American Association for Cancer Research (2001) πŸ”¬, and European Society of Medical Oncology (2012) 🌍. He also actively participates in cancer research initiatives, including the Cancer Moonshot Program (2016) πŸš€ and the Medical Oncology Association of Southern California (2022) 🌿.

Achievements

Dr. Edwin Posadas 🩺 has built a distinguished career in internal medicine and medical oncology, dedicated to advancing patient care and cancer research. In 2001, he became certified in Internal Medicine πŸ₯, laying the foundation for his expertise in diagnosing and managing complex diseases. His passion for oncology led him to further specialize, earning his Medical Oncology certification in 2019 πŸ§¬πŸŽ—οΈ. With decades of experience, he remains committed to innovative cancer treatments, translational research, and personalized patient care, making significant contributions to the oncology community through clinical practice, research, and professional collaborations. πŸ”¬πŸ’™

Research Focus

Dr. Edwin M. Posadas is a distinguished researcher specializing in prostate cancer πŸ”¬, metastasis 🧬, and nanotechnology-based diagnostics πŸ₯. His work focuses on understanding the molecular determinants of metastasis in prostate cancer, particularly liver and visceral metastases. He has contributed to the development of nanotechnology solutions for early cancer detection 🩸 and circulating tumor cell profiling. His research also explores the role of FYN kinase in cancer growth and motility. With multiple grants from the National Cancer Institute and Congressionally Directed Medical Research Programs, his pioneering work is advancing precision oncology and metastasis prevention in prostate cancer patients. πŸŽ—οΈ

Publication Top Notes